Skip to main content

ChondroGene Gets Conditional OK to Trade on Toronto Exchange; Will Change Name to GeneNews

NEW YORK (GenomeWeb News) – ChondroGene today said it has received “conditional approval” from Canadian regulators to list its common shares on the Toronto Stock Exchange.
 
The company, which must still file final documentation, said it expects to begin trading its common shares on the TSX by Oct. 31.
 
At that time ChondroGene will change its name to GeneNews and will trade under the symbol GEN, and ChondroGene’s common shares will cease trading on the TSX Venture Exchange.
 
ChondroGene received shareholder approval to change its name at its annual meeting June 12.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.